Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 41, Issue 5, 1998, Pages 838-844

  Horwitz, David A ^a   Gray, J Dixon ^a   Behrendsen, Steven C ^a   Kubin, Marek ^b   Rengaraju, Manthrasalam ^a   Ohtsuka, Kazuo ^a   Trinchieri, Giorgio ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; MONONUCLEAR CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CELLS, CULTURED; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MONOCYTES; RADIOIMMUNOASSAY; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031977667     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S     Document Type: Article

References (34)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams and Wilkins; 1997. p. 69-78.
2. Gladman DD, Urowitz MB. Prognostic subsets and mortality in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams and Wilkins; 1997. p. 1213-28.
3. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
4. Horwitz DA, Stohl W, Gray JD. T lymphocytes, NK cells and cytokines in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams and Wilkins; 1997. p. 155-94.
5. Horwitz DA, Jacob C. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994;16:181-200.
6. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB×NZW) F1 lupus-like nephritis with monoclonal antibody to γ-interferon. J Exp Med 1987;166:798-802.
7. Jacob CO, McDevitt HO. Tumor necrosis factor-a in murine autoimmune "lupus" nephritis. Nature 1988;33:356-8.
8. Zhang GX, Navikas V, Link H. Cytokines in the pathogenesis of myasthenia gravis. Muscle Nerve 1997;20:543-51.
9. Segal R, Bermas BL, Dayan M, Kalush F, Shearer GM, Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol 1997;158:3009-16.
10. Santiago ML, Fossati L, Jacquet C, Muller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 1997;185:65-70.
11. Fox CJ, Danska JS. IL-4 expression at the onset of islet inflammation predicts non-destructive insulitis in diabetic mice. J Immunol 1997;158:2414-24.
12. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13: 251-76.
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 1988;31:817-25.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
16. Denholm EM, Wolber FM. A simple method for the purification of human peripheral blood monocytes. J Immunol Methods 1991;144:247-51.
17. Hirokawa M, Gray JD, Takahashi T, Horwitz DA. Human resting B lymphocytes serve as accessory cells for anti-CD2 induced T cell activation. J Immunol 1992;149:1859-66.
18. Murphy M, Loudon R, Kobayashi M, Trinchieri G. Gamma interferon and lymphotoxin, released by activated T cells, synergize to inhibit granulocyte-monocyte colony formation. J Exp Med 1986;164:263-79.
19. Van der Pouw-Kraan T, de Jong R, Aarden L. Development of human Th1 and Th2 cytokine responses: the cytokine production profile of T cells is dictated by the primary in vitro stimulus. Eur J Immunol 1993;23:1-5.
20. Gerosa F, Paganin C, Peritt D, Paiola F, Scupoli MT, Astc-Amezaga M, et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-γ and interleukin-10. J Exp Med 1996;183:2559-69.
21. Kubin M, Kamoun M, Trinchieri G. Interleukin-12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994;180:211-22.
22. Cuturi MC, Murphy M, Costa-Giomi MP, Weinmann R, Perussia B, Trinchieri G. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med 1987;165:1581-94.
23. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste-Amezaga M, et al. Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-98.
24. Huang YP, Miescher PA, Zubler RH. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 1986;137:3515-20.
25. Moore KW, O'Garra A, de Waal Malefyt R, Vieria P, Mossman TR. Interleukin-10. Annu Rev Immunol 1993;11:165-90.
26. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
27. Horwitz DA, Gray JD, Ohtsuka K, Hirokawa M, Takahashi T. The immunoregulatory effects of natural killer cells: the role of TGFβ and implications for autoimmunity. Immunol Today 1997;18:538-42.
28. Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990;33:1216-25.
29. Linker-Israeli M, Bakke AC, Quismorio FP, Horwitz DA. Correction of interleukin 2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells. J Clin Invest 1985;75:762-8.
30. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996;5:285-93.
31. Horwitz DA, Tang FL, Stimmler MM, Oki A, Gray JD. Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: evidence for impaired T cell-accessory cell interaction. Arthritis Rheum 1997;40:822-33.
32. Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28+ T cells in systemic lupus erythematosus. Clin Exp Immunol 1996;106:218-29.
33. Tsokos GC, Kovacs B, Sfikakis PP, Theocharis S, Vogelgesang S, Via CS. Defective antigen-presenting cell function in patients with systemic lupus erythematosus: role of the B7-1 (CD80) costimulatory molecule. Arthritis Rheum 1996;39:600-9.
34. Garcia Cozar FJ, Molina IJ, Cuadrado MJ, Maarubayashi M, Pena J, Santamaria M. Defective B7 expression on antigen-presenting cells underlying T cell activation in systemic lupus erythematosus patients. Clin Exp Immunol 1996;104:72-9.